Preservative exposure and surgical outcomes in glaucoma patients: The PESO study

Journal of Glaucoma

Volumn 22, Issue 9, 2013, Pages 730-735

  Boimer, Corey ^a   Birt, Catherine M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

benzalkonium chloride; preservative exposure; trabeculectomy outcome

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; ATROPINE; BENZALKONIUM CHLORIDE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; COSOPT UNIT DOSE; DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; FLUOROURACIL; KETOROLAC TROMETAMOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; MITOMYCIN; PREDNISOLONE ACETATE; TIMOLOL; TIMOLOL MALEATE; TOBRAMYCIN; TRAVOPROST; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; BENZALKONIUM; PRESERVATIVE;

ADULT; AGED; ARTICLE; CATARACT; EVENING DOSAGE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; IRIDECTOMY; LENS IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PHACOEMULSIFICATION; PHACOTRABECULECTOMY; POLYGLACTIN SUTURE; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; REOPERATION; RISK ASSESSMENT; SURGICAL RISK; SURGICAL TECHNIQUE; SURVIVAL TIME; SUTURING METHOD; TRABECULECTOMY; TRABECULOPLASTY; TREATMENT FAILURE; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POSTOPERATIVE COMPLICATIONS; PRESERVATIVES, PHARMACEUTICAL; RETROSPECTIVE STUDIES; RISK FACTORS; TRABECULECTOMY; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890558768     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31825af67d     Document Type: Article

References (27)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90: 262-267
2. Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001;10: 237-249
3. Broadway DC, Grierson I, O'Brian C, et al. Adverse effects of topical antiglaucoma medication: II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112: 1446-1454
4. Flach AJ. Does medical treatment influence the success of trabeculectomy? Trans Am Ophthalmol Soc. 2004;102: 219-224
5. Baudouin C. Detrimental effect of preservatives in eye drops: Implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86: 716-726
6. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervations and morphology. Am J Ophthalmol. 2009;147: 725-735
7. Baudouin C. The ocular surface in glaucoma. Cornea. 2009; 28: S14-S19
8. Baudouin C, Riancho L, Warnet J, et al. In vitro studies of antiglaucomatous prostaglandin analogues: Travaprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48: 4123-4128
9. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZiapreserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27: 837-845
10. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res. 2010;29: 312-334
11. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18: 205-215
12. Broadway DC, Grierson I, O'Brian C, et al. Adverse effects of topical antiglaucoma medication: II. The conjunctival cell profile. Arch Ophthalmol. 1994;112: 1437-1445
13. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles, and preservatives. Surv Ophthalmol. 1980;25: 15-30
14. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the shortterm effects on the human corneal surface of topical timilol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12: 486-490
15. Schuman JS. Antiglaucoma medications: A review of safety and tolerability issues related to their use. Clin Ther. 2000;22: 167-208
16. Yamazaki S, Nanno M, Kimura T, et al. Effects of switching to SofZia-preserved travaprost in patients who presented with superficial punctuate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol. 2010;54: 7-14
17. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: A comparison of safety and efficacy. J Glaucoma. 2007;16: 98-103
18. Easty DL, Nemeth-Wasmer G, Vounatsos JP, et al. Comparison of a nonpreserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol. 2006;90: 574-578
19. Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics study. Acta Ophthalmol. 2008;242: S14-S19
20. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol. 2008; 242: S7-S13
21. Mietz H, Raschka B, Krieglstein GK. Risk factors for failures of trabeculectomies performed without antimetabolites. Br J Ophthalmol. 1999;83: 814-821
22. Dally LG, Ederer F, Gaasterland DE, et al. The advanced glaucoma intervention study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol. 2002;134: 481-498
23. Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32: 149-170
24. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108: 1943-1953
25. Baudouin C, Nordmann JP, Denis P, et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol. 2002;240: 929-935
26. Broadway DC, Grierson I, Sturmer J, et al. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996;114: 262-267
27. Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: A randomized controlled trial. Ophthalmology. 2010;117: 1324-1330